This episode explores the significant regulatory hurdles Korean medical device manufacturers face when entering the Brazilian market. We detail the extended approval timelines and unpredictable delays from Brazil's ANVISA, contrasting them with the more streamlined processes of Korea's MFDS. Learn about the different registration pathways for various device classes and the strategic adjustments necessary for a successful market entry.

Key Questions:

- Why is Brazil's regulatory timeline a major challenge for Korean MedTech companies?

- How do ANVISA's approval processes for high-risk devices differ from Korea's MFDS?

- What are the typical registration timelines for Class I, II, III, and IV devices in Brazil?

- What is the difference between the 'Notificação' and 'Registro' pathways?

- How must Korean companies adapt their business strategies to account for Brazilian regulatory uncertainty?

- How long does a medical device registration remain valid in Brazil?

- What are the ongoing compliance responsibilities after receiving ANVISA approval?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We combine local expertise across 30+ markets with advanced AI to streamline regulatory strategy, technical dossier submission, and post-market surveillance. Our integrated approach allows a single registration process to unlock multiple markets, saving you time and resources. Whether you're a startup or a multinational enterprise, our solutions are tailored to your needs. Contact Pure Global at [email protected], visit our website at https://pureglobal.com, or explore our FREE AI tools and database at https://pureglobal.ai.